Enhanced Cytotoxicity of RIPTK Gene Therapy of Pancreatic Cancer via PDX-1 Co-Delivery

Journal of Surgical Research

Volumn 137, Issue 1, 2007, Pages 1-9

  Liu, Shihe ^a   Wang, Xiao Ping ^a   Brunicardi, F Charles ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

adenovirus; cytotoxicity; gene therapy; pancreatic cancer; PDX 1; rat insulin promoter

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; GANCICLOVIR; LIPOSOME; PLASMID DNA; TRANSCRIPTION FACTOR PDX 1;

ADENOVIRUS VECTOR; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HOMEODOMAIN PROTEINS; HUMANS; INSULIN; LAC OPERON; MICE; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RATS; TRANS-ACTIVATORS; TRANSFECTION;

EID: 33845295106     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.04.039     Document Type: Article

References (62)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8
2. Lowenfels A.B., and Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34 (2004) 238
3. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 3 (1998) E214
4. Howes N., Lerch M.M., Greenhalf W., et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2 (2004) 252
5. Minamoto T., Mai M., and Ronai Z. K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers: A review. Cancer Detect Prev 24 (2000) 1
6. Ishida T., Tsujisaki M., Hanzawa Y., et al. Significance of erbB-2 gene product as a target molecule for cancer therapy. Scand J Immunol 39 (1994) 459
7. Bansal P., and Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109 (1995) 247
8. Masamune A., Mizutamari H., Kume K., Asakura T., Satoh K., and Shimosegawa T. Hereditary pancreatitis as the premalignant disease: A Japanese case of pancreatic cancer involving the SPINK1 gene mutation N34S. Pancreas 28 (2004) 305
9. Fisher W. Diabetes: Risk factor for the development of pancreatic cancer or manifestation of the disease?. World J Surg 25 (2001) 503
10. Frye J.N., Inder W.J., Dobbs B.R., and Frizelle F.A. Pancreatic cancer and diabetes: Is there a relationship?. A case-controlled study. Aust N Z J Surg 70 (2000) 722
11. Aoki K., Yoshida T., Matsumoto N., et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 8 (1997) 1105
12. Block A., Chen S.H., Kosai K., Finegold M., and Woo S.L. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 15 (1997) 25
13. Bouvet M., Bold R.J., Lee J., et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [see comments]. Ann Surg Oncol 5 (1998) 681
14. Calbo J., Marotta M., Cascallo M., et al. Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 8 (2001) 740
15. Carrio M., Romagosa A., Mercade E., et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 6 (1999) 547
16. Clary B.M., Coveney E.C., Philip R., et al. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther 4 (1997) 97
17. Kawakami Y., Okada T., and Akada M. Development of immunotherapy for pancreatic cancer. Pancreas 28 (2004) 320
18. Manu M., Buckels J., and Bramhall S. Molecular technology and pancreatic cancer. Br J Surg 87 (2000) 840
19. Tamada K., Wang X.P., and Brunicardi F.C. Molecular targeting of pancreatic disorders. World J Surg. 29 (2005) 325
20. Deharvengt S., Wack S., Uhring M., Aprahamian M., and Hajri A. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2′-deoxyriboside. Pancreas 28 (2004) E54
21. Fogar P., Greco E., Basso D., et al. Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol 29 (2003) 721
22. Greco E., Fogar P., Basso D., et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: An incomplete antitumor effect. Pancreas 25 (2002) e21
23. Hajri A., Wack S., Lehn P., et al. Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes. Cancer Gene Ther 11 (2004) 16
24. Kanyama H., Tomita N., Yamano T., et al. Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res 61 (2001) 14
25. Wang J., Lu X.X., Chen D.Z., Li S.F., and Zhang L.S. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J Gastroenterol 10 (2004) 400
26. Tirone T.A., Wang X.P., Templeton N.S., et al. Cell-specific cytotoxicity of human pancreatic adenocarcinoma cells using rat insulin promoter thymidine kinase-directed gene therapy. World J Surg 28 (2004) 826
27. Li Z., Ding Q., Li Y., Miller S.A., Abbruzzese J.L., and Hung M.C. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Cancer Lett 1006 236 (2005) 58 Jun 13
28. Deharvengt S., Wack S., Aprahamian M., and Hajri A. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med 7 (2005) 672
29. Yang L., Cao Z., Li F., Post D.E., Van Meir E.G., Zhong H., and Wood W.C. Tumor-specific gene expression using the surviving promoter is further increased by hypoxia. Gene Ther 11 (2004) 1215
30. Wang X.P., Yazawa K., Yang J., Kohn D., Fisher W.E., and Brunicardi F.C. Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. J Gastrointest Surg 8 (2004) 98 discussion 106
31. Wesseling J.G., Yamamoto M., Adachi Y., et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther 8 (2001) 990
32. Harris J.D., Gutierrez A.A., Hurst H.C., Sikora K., and Lemoine N.R. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1 (1994) 170
33. DiMaio J.M., Clary B.M., Via D.F., Coveney E., Pappas T.N., and Lyerly H.K. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116 (1994) 205
34. Facfarlane W.M., Shepherd R.M., Cosgrove K.E., James R.F., Dunne M.J., and Docherty K. Glucose modulation of insulin mRNA levels is dependent on transcription factor PDX-1 and occurs independently of changes in intracellular Ca2+. Diabetes 49 (2000) 418
35. Gao Y., Miyazaki J., and Hart G.W. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. Arch Biochem Biophys 415 (2003) 155
36. Glick E., Leshkowitz D., and Walker M.D. Transcription factor BETA2 acts cooperatively with E2A and PDX1 to activate the insulin gene promoter. J Biol Chem 275 (2000) 2199
37. Wang H., Maechler P., Ritz-Laser B., et al. Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation. J Biol Chem 276 (2001) 25279
38. Shinozuka Y., Okada M., Oki T., et al. Altered expression of HES-1, BETA2/NeuroD, and PDX-1 is involved in impaired insulin synthesis induced by glucocorticoids in HIT-T15 cells. Biochem Biophys Res Commun 287 (2001) 229
39. Mosley A.L., Corbett J.A., and Ozcan S. Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol Endocrinol 18 (2004) 2279
40. Offield M.F., Jetton T.L., Labosky P.A., et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 122 (1996) 983
41. Ohneda K., Mirmira R.G., Wang J., Johnson J.D., and German M.S. The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol 20 (2000) 900
42. Koizumi M., Doi R., Toyoda E., et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 134 (2003) 260
43. Frazier M. Gene expression in pancreatic adenocarcinoma. Ann N Y Acad Sci 880 (1999) 1
44. Wang X.P., Li Z.J., Magnusson J., and Brunicardi F.C. Tissue MicroArray analyses of pancreatic duodenal homeobox-1 (PDX-1) in human cancers. World J Surgery 29 (2005) 334
45. Wang X.P., Yazawa K., Templeton N.S., et al. Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice. World J Surg 29 (2005) 339
46. Ashizawa S., Brunicardi F.C., and Wang X.P. PDX-1 and the pancreas. Pancreas 28 (2004) 109
47. Tirone T.A., Fagan S.P., Templeton N.S., Wang X., and Brunicardi F.C. Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapy. Ann Surg 233 (2001) 603
48. Chen L., Liu Q., Qin R., et al. Amplification and functional characterization of MUC1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hSSTR2 gene in MUC1-positive Panc-1 pancreatic cancer cells in vitro. Int J Mol Med 15 (2005) 617
49. Ilies M.A., Johnson B.H., Makori F., et al. Pyridinium cationic lipids in gene delivery: An in vitro and in vivo comparison of transfection efficiency versus a tetraalkylammonium congener. Arch Biochem Biophys 435 (2005) 217
50. Kaiser S., and Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res 38 (2001) 133
51. Makinen K., Loimas S., Kosma V.M., et al. Adenovirus-mediated gene transfer into an experimental pancreatic tumour. Ann Chir Gynaecol 89 (2000) 99
52. Vorburger S.A., and Hunt K.K. Adenoviral gene therapy. Oncologist 7 (2002) 46
53. Aoki A., Tsukada T., Yasuda H., et al. Multiple endocrine neoplasia type 1 presented with manic-depressive disorder: A case report with an identified MEN1 gene mutation. Jpn J Clin Oncol 27 (1997) 419
54. Chen S.H., Shine D., Goodman J., Grossman R., and Woo S. Gene Therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acd Sci USA 91 (1994) 3054
55. Makinen K., Loimas S., Wahlfors J., Alhava E., and Janne J. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J Gene Med 2 (2000) 361
56. Qian C., Bilbao R., Bruna O., and Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simples virus thymidine kinase. Hepatology 22 (1995) 118
57. Ramesh R., Saeke T., Templeton N.S., et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 3 (2001) 337
58. Yang L., Hwang R., Chiang Y., Gordon E.M., Anderson W.F., and Parekh D. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clin Cancer Res 4 (1998) 731
59. Ramirez P.J., and Vickers S.M. Adenoviral gene therapy for pancreatic adenocarcinoma. Curr Surg 61 (2004) 351
60. Pearson A.S., Koch P.E., Atkinson N., et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 5 (1999) 4208
61. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997) 1320
62. Curiel D.T. Considerations and challenges for the achievement of targeted gene delivery. Gene Ther 6 (1999) 1497